- The drug substance industry eliminates hidden dangers
- The transformation of APIs depends on many factors. Innovation is the key.
- Improving the domestic pharmaceutical innovation market system is the prerequisite for the transform
- China's hormonal API exports stepped into the normal trade track
- Innovation in the API industry requires both corporate and government
According to China Customs statistics, in 2014, the export value of hormonal APIs in China increased by 52.99% year-on-year, achieving the largest increase since the European debt crisis. It can be seen that with the continuous recovery of the main European economy, the export of hormonal APIs in China has been followed. Into the normal trade track.
In recent years, due to the increase of domestic clinical application and the development of aquaculture industry, the production of hormonal APIs has increased year by year, and the industry has developed rapidly. It is believed that with the continuous advancement of China's medical technology, hormone-based APIs will have more development prospects.
The price and price are divided
In 2014, the export volume of hormonal APIs in China increased by 86.5% year-on-year, while the average export price decreased by 17.79%. Therefore, the analysis shows that although the European economic recovery has brought good benefits to China's pharmaceutical export trade, the foreign buyer's capital chain is still tense. So that the profits of our export enterprises are squeezed.
In 2014, China's hormonal APIs were exported to 112 countries and regions, of which: the export value to Asia increased by 46.43% year-on-year; the export value to Europe increased by 78.67%. The above two continents are the main export markets for hormonal APIs in China, accounting for 80.12%. In 2014, China's top 10 trading partners were India, the United States, Italy, the Netherlands, Belgium, Germany, Switzerland, the United Kingdom, Spain, and Brazil. The 10 countries accounted for 71.24% of the total export of hormonal APIs in China.
In 2014, there were 510 enterprises engaged in the export trade of hormone raw materials in China. Among them, 393 private enterprises accounted for 47.7% of the export value, accounting for half of China's hormonal bulk drug exports and 49 foreign-funded enterprises, accounting for 24.91% of exports. Tianjin Tianfa Pharmaceutical Import and Export Corporation, Changzhou Jiaerke Pharmaceutical, Zhejiang Xianyi Pharmaceutical, Zhejiang Xianju Junye Pharmaceutical, Zhejiang Tiantai County Aoruite Pharmaceutical, Henan Lihua Pharmaceutical, Hunan Chemicals The company, Zhejiang Xianju Xianle Pharmaceutical, Jiangxi Hongyuan Pharmaceutical Raw Materials Company, and Tianjin Jinjin Pharmaceutical occupy the top 10 rankings of China's hormone raw material export enterprises. Zhejiang, Tianjin and Jiangsu rank among the top three in exporting provinces and cities, and the export value accounts for 62.09%, reflecting a very high market concentration.
Hormone drugs are broadly defined as drugs that use human or animal hormones (including organic compounds with the same hormone structure and principle of action) as active ingredients. Usually, the "hormone drugs" in the doctor's mouth are generally referred to as adrenal glucocorticoid drugs, and other hormonal drugs are commonly used for their taxonomic names such as androgen, insulin, and growth hormone.
In 2014, the top 10 exporters of hormonal raw materials in China were: other female hormones and progesterone; cortisone, hydrocortisone, dehydrocortisone and dehydropicol; other cortex Halogenated derivatives of steroid hormones; other steroid hormones and their derivatives and structural analogues; dexamethasone; gonadotropin; danazol; dehydrochloromethyltestosterone (including androsten-1-ene-3,17 -dione, (Δ) androstenediol, prasinone, deoxymethyltestosterone); miBone, norronone, nourone, norstib (including 19-nor-androstenediol, 19 - norranoxene dione, noroxine; other hormones and their derivatives and structural analogs.
Hydrocortisone and dexamethasone are still the major varieties of hormonal APIs exported in China. The export value accounts for about 30%. In 2014, the export volume and price of hydrocortisone decreased by 5.57% and 8.04% respectively. The market is: Asia, Europe and North America, the export value accounted for 88.82%, India, Italy, the United States, Spain, Germany in the export countries ranked the top 5, the export amount accounted for 53.72%.
The top 5 exporting companies are Tianjin Tianfa Pharmaceutical, Henan Lihua Pharmaceutical, Zhejiang Xianyi Pharmaceutical, Tianjin Jinjin Pharmaceutical, and Lijiang Yinghua Biological, accounting for 79.97% of the total export value.
The export volume of dexamethasone increased by 9.37%, and the export price decreased by 6.43%. The export value of Africa and Latin America as emerging markets increased by 67.58% and 31.12% respectively, which became a highlight of the 2014 export of dexamethasone. The top five exporting countries are all Asian markets, namely India, Indonesia, Malaysia, Singapore, and Pakistan, with an export value of 59.07%.
The top 5 exporting companies are Tianjin Tianfa Pharmaceutical, Zhejiang Xianyi Pharmaceutical, Zhejiang Xianju Junye Pharmaceutical, Zhejiang Xianju Xianle Pharmaceutical, and Hengshi Group, with an export value of 89.11%.
China is a major exporter of hormonal bulk drugs and has a dominant position in the international market. It is predicted that in 2015, the weakening trend of the European and Japanese economies in the international market will be difficult to change in the short term. The emerging markets and small and medium-sized emerging economies will generally perform poorly. The decline in commodity prices will inevitably lead to weak market demand and global liquidity tightening, making the world The trend of economic differentiation is obvious.
On the domestic front, the downward pressure on the overall economy has increased, the planting area of the upstream raw material turmeric has decreased and the environmental protection requirements have increased the cost. All these unfavorable factors have cast a shadow over the recovery of the export of hormonal raw materials, and the enterprises rely on the traditional model to export. The possibility of profit in the market is not great. Therefore, China's hormonal API business enterprises must change the traditional marketing model, accelerate the industrial transformation, from low-cost competition to quality and technology competition, increase the development of high-end products, break down the competitive pressure of low-end products, and create their own Brand products, strive for more international market share, improve the export efficiency of China's hormonal APIs, and promote the balanced development of industrial supply and demand.